Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF

Sarcoidosis Vasculitis and Diffuse Lung Disease

Volumn 16, Issue 2, 1999, Pages 209-214

  Nagai, Sonoko ^a   Kitaichi, Masanori ^b   Hamada, Kunio ^a   Nagao, Taisi ^a   Hoshino, Yuma ^a   Miki, Hiroyuki ^a   Izumi, Taketeru ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Idiopathic pulmonary fibrosis (IPF); Japanese patients; Retrospective analysis of survival rates; Surgical lung biopsy and autopsy

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; IDIOPATHIC DISEASE; JAPAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADRENAL CORTEX HORMONES; AGED; COHORT STUDIES; DYSPNEA; EXERTION; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0032862137     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Cherniack RM, Crystal RG, Kalica AR: Current concepts in idiopathic pulmonary fibrosis: A road map for the future. Am Rev Respir Dis 1991; 143: 680-683.
2. King TE Jr. Idiopathic pulmonary fibrosis. In: Schwartz MI, King TE Jr., (Eds.) Interstitial lung disease, 2nd ed., Mosby Year Book. St. Louis, 1993; 376-403.
3. Davis GS: Idiopathic pulmonary fibrosis: Current concepts and management. In Tierney DF, (Ed), Current Pulmonology. Mosby Year Book, St. Louis, 1993; 321-356.
4. Johnston IDA, Prescott RJ, Chalmers JC et al: British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52: 38-44.
5. Sulavik SB: A clinician's view. In Phan HP, Thrall RS. (Eds.) Pulmonary fibrosis. Marcel Dekker, New York, 1995; 1-58.
6. Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994; 150: 967-972.
7. Johnston I, Britton J, Kinnear W, Logan R: Rising mortality from cryptogenic fibrosing alveolitis. Br Med J 1990; 301: 1017-1021.
8. Louw SJ, Bateman ED, Benatar SR: Cryptogenic fibrosing alveolitis. Clinical spectrum and treatment S. Afr Med J 1984; 65: 195-200.
9. Tukiainen P, Taskinen E, Korhola O, Holsti P, Valle M: Prognosis of cryptogenic fibrosing alveolitis. Thorax 1933; 38: 349-355.
10. Jindal SK, Malik SK, Deodhar SD, Sharma BK: Fibrosing alveolitis: a report of 61 cases seen over the past five years. Indian J Chest Dis Allied Sci 1979; 21: 174-179.
11. Raghu G, Hert R: Interstitial lung diseases: genetic predisposition and inherited interstitial lung diseases. Semin Resp Med 1993; 14: 323-332.
12. Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, Gupta RG: Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801-809.
13. Turner-Warwick M, Burrows B, Johnson A: Cryptogenic fibrosing alveolitis: Clinical features and their influence on survival. Thorax 1980; 35: 171-180.
14. Crystal RG, Fulmer JD, Roberts WC: Idiopathic pulmonary fibrosis: Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85: 769-788.
15. Watters LC, Schwarz MI, Cherniack RM et al: Idiopathic pulmonary fibrosis: Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135: 696-704.
16. Peterson MW, Monick M, Hunninghake GW: Prognostic role of eosinophils in pulmonary fibrosis. Chest 1987; 92: 51-56.
17. Liebow A: Definition and classification of interstitial pneumonias in human pathology. Prog Resp Res 1975; 8: 1-33.
18. Colby TV, Lombard C, Yousem SA, Kitaichi M: Atlas of Pulmonary Surgical Pathology. WB Saunders, Philadelphia, 1991; p. 228-306.
19. Katzenstein ALA, Myers JL: Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. State of the Art. Am J Respir Crit Care Med 1998; 157: 1301-1315.
20. Bjoraker JA, Ryu JH, Edwin MK et al: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
21. Nagai S, Kitaichi M, Nishimura K, Itoh H, Izumi T, Colby TV: Idiopathic Nonspecific Interstitial Pneumonia/Fibrosis: Comparison with Idiopathic Pulmonary Fibrosis and bronchiolitis Obliterans Organizing Pneumonia. Eur Resp J 1998; 12: 1-10.
22. Raghu G: Idiopathic pulmonary fibrosis: a rational clinical approach. Chest 1987; 92: 148-154.
23. Hubbard R, Johnston I, Britton J: Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396-400.
24. Doherry MJ, Pearson MG, O'Grady EA, Pellegrini V, Calverley PM: Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52: 998-1002.
25. Schwartz DA, Helmers RA, Galvin JR et al: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 450-454.
26. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr: Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396-404.
27. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A: Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496-499.
28. Hunninghake GW, Kalica AR: Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 915-918.
29. Douglas WW, Ryu JH, Swensen SJ, et al: and Members of the Lung Study Group: Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 158: 220-225.